Navigation Links
Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
Date:11/19/2012

AUSTIN, Texas, Nov. 19, 2012 /PRNewswire/ -- On November 16, 2012, the Delaware Court of Chancery has dismissed with prejudice a lawsuit brought against Vermillion, Inc. and its board of directors by dissident stockholders, Gyorgy B. Bessenyei and Robert S. Goggin, III.

Following the decision, a proxy filed with the Securities Exchange Commission (SEC) by an alleged stockholder group led by Bessenyei and Goggin describes Goggin as "honest and trustworthy." However, the Delaware Court of Chancery court issued findings to the contrary. The court ruled that Goggin and Bessenyei had illegally falsified documents and, moreover, that the conduct of Goggin appeared to be a violation of the Pennsylvania rules of professional conduct applicable to Pennsylvania lawyers.

With the suit now dismissed with prejudice, which disallows its re-filing, Vermillion can move forward with the company's annual meeting. The meeting had been delayed due to the Bessenyei and Goggin lawsuit, which prohibited the company from holding a meeting until the matter was resolved. The company will provide further details regarding the annual meeting once a meeting and record date is set by the board of directors. The company will propose one director for the single seat up for election.

Important Additional Information
In connection with its 2012 annual meeting of stockholders, Vermillion will file with the SEC a definitive proxy statement and other documents regarding the 2012 annual meeting, and will also mail to each stockholder of record entitled to vote at the 2012 annual meeting the definitive proxy statement and a proxy card. STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE COMPANY'S 2012 DEFINITIVE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. When they are available, the definitive proxy statement and other documents relating to the 2012 annual meeting of stockholders may be obtained free of charge from the SEC's Electronic Data Gathering Analysis and Retrieval system ("EDGAR") at www.sec.gov or from Vermilion's website at www.vermillion.com, under Investors – SEC Filings.

The company and its directors, director nominee and executive officers may be deemed to be participants in the solicitation of proxies in connection with the company's 2012 annual meeting of stockholders. Detailed information concerning the company's directors, director nominee and officers is available in the company's amended preliminary proxy statement for its 2012 annual meeting of stockholders filed with the SEC on May 17, 2012, as well as in other public filings made by the company with the SEC. Additional information regarding the company's directors, director nominee, executive officers and other persons who may, under the rules of the SEC, be considered to be participants in the solicitation of proxies for the 2012 annual meeting of stockholders, including their respective interests by security holdings or otherwise, will be set forth in the definitive proxy statement for the company's 2012 annual meeting of stockholders when it is filed with the SEC.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Forward-Looking Statements
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission (SEC). All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in the company's most recent reports on Form 10-K and Form 10-Q. Copies are available through EDGAR at www.sec.gov.

Investor Relations:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
info@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
2. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
3. Lilly Statement on Affordable Care Act Ruling by Supreme Court
4. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
5. Attorneys for Class of Female VPs and SVPs Employed by PR Giant MSLGroup Clarify Companys Inaccurate Description of Federal Courts Recent Certification Ruling
6. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
7. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
8. Federal Appeals Court Upholds Fraud Verdict Against Cornell University Medical School For Misuse Of NIH Aids Funding
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
11. Vermillion Announces CEO Succession Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and ... driving up healthcare costs and threatening outcomes, were problems ... supply and IVD industry that support them, met this ... market researcher said that drugs of abuse, procalcitonin and ... sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Inc. Magazine Unveils 36th Annual List ... with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. ... most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique ...
(Date:8/17/2017)... ... ... Momkus McCluskey Roberts LLC recently announced it was naming attorney ... firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined Momkus McCluskey ... employment litigation, commercial litigation and business disputes. Her experience includes all aspects of litigation ...
(Date:8/17/2017)... Yorba Linda, Ca (PRWEB) , ... August 17, 2017 , ... ... centrifuges are useful tools in the laboratory that we can no longer do without. ... to prolong the lifetime of your device. , In this webinar, attendees will learn ...
(Date:8/17/2017)... Yorba Linda, Ca (PRWEB) , ... August 17, 2017 , ... ... by the FDA to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. ... their 21 CFR Part 11 ruling. , Presented as part of the ...
(Date:8/16/2017)... ... , ... Summer days spent with family are priceless. Since August is Family ... enjoying the season of sunshine. Add trying something new to this summer’s bucket list. ... on the fun. , Try Something New , Choose an activity ...
Breaking Medicine News(10 mins):